This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim's SYNCHRONIZE program. The glucagon receptor component is the differentiator: while GLP-1 agonists reduce appetite and slow gastric emptying, glucagon receptor activation drives thermogenic energy expenditure in adipose tissue — burning fat through a second, complementary mechanism. Phase 2 data showed ~19% weight loss at 46 weeks and an 83% MASH resolution rate, positioning it as both a weight loss agent and a leading MASH treatment candidate.
Survodutide is Boehringer Ingelheim's investigational dual agonist — engineered to activate both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GcgR) with balanced affinity. Each receptor does something distinct. GLP-1R activation drives satiety, reduces appetite, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. GcgR activation does something the GLP-1 class alone cannot: it directly increases energy expenditure in hepatic tissue and adipose tissue via thermogenic pathways — essentially activating fat burning rather than just reducing food intake.
The combination is metabolically synergistic. GLP-1 reduces the calories going in; glucagon receptor activation increases the calories being burned. The result in Phase 2 clinical trials: ~19% weight loss at 46 weeks — competitive with tirzepatide's Phase 2 numbers and achieved with a different mechanism that also happens to clear liver fat aggressively.
The MASH (Metabolic dysfunction-Associated SteatoHepatitis, formerly NASH) data is what makes survodutide particularly notable. Phase 2 results showed 83% MASH resolution without worsening of fibrosis — a level of hepatic response that has generated significant clinical interest. MASH affects an estimated 6.5% of the U.S. adult population and has limited treatment options; survodutide is one of a small number of pipeline candidates showing this magnitude of effect.
Glucagon alone would raise blood glucose (it's a counter-regulatory hormone). Survodutide co-activates GLP-1R and GcgR simultaneously — the insulin-secreting GLP-1 effect offsets the glucagon-driven glucose rise, preserving the thermogenic and hepatic benefits of glucagon receptor activation without the hyperglycemia. This is the pharmacological challenge Boehringer Ingelheim solved in the survodutide formulation.
Phase 2 dose-ranging trial across 4.8mg, 3.6mg, 2.4mg, and 1.2mg weekly doses. The 4.8mg cohort showed ~19% weight loss at 46 weeks. Phase 3 SYNCHRONIZE program is enrolling with outcomes expected 2025–2026.
The headline finding: 83% MASH resolution without worsening of fibrosis in Phase 2. MASH (formerly NASH) is a progressive liver disease driven by fat accumulation and inflammation — survodutide's GcgR-mediated hepatic fat oxidation provides a mechanistic explanation for the strong liver response.
Unlike GLP-1-only drugs, survodutide activates energy expenditure pathways rather than just reducing intake. Glucagon receptor activation in adipose tissue drives thermogenesis — relevant for body composition research beyond simple caloric deficit models.
SYNCHRONIZE-CVOT is evaluating cardiovascular outcomes — particularly relevant given MASH's strong association with cardiometabolic risk. The combination of weight reduction, hepatic fat clearance, and metabolic improvement makes CV endpoints a logical focus area.
Combination effects on insulin sensitivity, hepatic fat, visceral adiposity, and dyslipidemia make survodutide a broad-spectrum metabolic research tool. The GcgR arm drives improvements that GLP-1 agonists alone produce less reliably.
MASH resolution without worsening fibrosis is the critical regulatory endpoint for liver disease drugs. Survodutide's Phase 2 data hit this bar with an 83% response rate — a result that places it among the top pipeline candidates for a condition affecting tens of millions.
Body weight reduction at 46 weeks in the highest dose cohort of the Phase 2 dose-ranging trial. Competitive with tirzepatide Phase 2 outcomes; Phase 3 SYNCHRONIZE program is the confirmatory step.
MASH resolution without worsening of fibrosis at 24 weeks in Phase 2. This is among the highest response rates reported for any MASH pipeline candidate and is the primary driver of clinical excitement about survodutide's hepatic potential.
Glucagon receptor co-agonism is what separates survodutide from the GLP-1 class. Energy expenditure increase — not just appetite reduction — is the mechanism behind both the strong weight loss and the hepatic fat clearance observed in trials.
Survodutide is administered as a once-weekly subcutaneous injection. The Phase 2 trial evaluated doses from 1.2mg to 4.8mg weekly, with the highest dose showing the greatest weight loss. Titration from a low starting dose is essential — both GLP-1 and glucagon receptor activation contribute to early GI side effects (nausea, vomiting, diarrhea), and slow escalation improves tolerability without compromising long-term outcomes.
| Titration Step | Dose | Duration | Notes |
|---|---|---|---|
| Week 1–4 | 0.6mg SC weekly | 4 weeks | Starting dose. GI adjustment period — nausea is most common in weeks 1–2 and typically subsides. Do not advance if GI symptoms are unmanaged. |
| Week 5–8 | 1.2mg SC weekly | 4 weeks | First maintenance option or step toward higher doses. Some protocols hold here if weight loss response is adequate. |
| Week 9–12 | 2.4mg SC weekly | 4 weeks | Mid-range dose used in Phase 2. Meaningful metabolic effects observed; appropriate endpoint for many research applications. |
| Week 13–16 | 3.6mg SC weekly | 4 weeks | Pre-maintenance escalation. GI tolerability reassessment at each step before advancing. |
| Week 17+ | 4.8mg SC weekly | Maintenance | Maximum Phase 2 dose — associated with ~19% weight loss and 83% MASH resolution in trials. Cycle length in SYNCHRONIZE trials: 46+ weeks. |
Survodutide already contains GLP-1 receptor activity — adding a separate GLP-1 agonist (semaglutide, tirzepatide) would produce overlapping GLP-1R stimulation without additional benefit and with increased GI risk. Complementary pairings that work through different mechanisms:
Do not combine with semaglutide or tirzepatide — overlapping GLP-1R activation without additive benefit and increased GI burden.
Third-party COA, Finnrick-verified purity. Available in 4.8mg vials. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.